Screener
ANI Pharmaceuticals ANIP Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's cash & equivalents?
- ANI Pharmaceuticals (ANIP) reported cash & equivalents of $360.25M in Q2 2026.
- How has ANI Pharmaceuticals's cash & equivalents changed year-over-year?
- ANI Pharmaceuticals's cash & equivalents increased by 65.4% year-over-year, from $217.83M to $360.25M.
- What is the long-term trend for ANI Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's cash & equivalents has grown at a 105.1% compound annual growth rate (CAGR), from $7.86M to $285.62M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about ANI Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude